Over the past five years public health agenc ies have begun to examine how advanc es in genetic researc h c an be used to prevent disease and improve the health of the population. On the other side, dramatic strides in unraveling the environmental influenc es on c lassic c omplex c ardiovasc ular disease have translated into major public health efforts to alter lifestyle and diet. Furthermore, the advanc es in c ardiovasc ular genetic s -basic researc h in the biology of lipid metabolism, have led to drugs that c hange the natural history of disease progression. Although the drop in death rates from c ardiovasc ular disease represents one of the major vic tories for the twentieth-c entury medic ine, the prevalenc e of disease remains high, espec ially in CEE and SEE c ountries.
Classic al epidemiologic al studies have validated a set of c riteria that are widely employed in evaluation and management of patients at risk for c ardiovasc ular disorders. The lessons learned from risk assessment of bioc hemic al markers for atherosc lerosis are expec ted to be important in developing strategy to integrate genetic s into public health polic ies and national strategy for prevention of c ardiovasc ular disease. A framework for applying human genome researc h to disease prevention inc ludes genetic epidemiology, development of sc reening of target populations, ethic al, soc ioec onomic and legal implic ations, training and educ ation of professionals and public . Genetic influenc e on phenotypes c an be c lassified as monogenic or polygenic . Both mec hanisms c an c ontribute to risk for c ardiovasc ular disease as illustrated in Figure 1 
Cholesterol, plasma lipids and lipoproteins
It is now well known that the phenotypic variation in c holesterol c onc entrations in a population is determined by both genetic and environmental fac tors and that the mean and the 'normal' range of total plasma c holesterol levels vary in different populations. As the total c onc entrations inc rease throughout the range observed in the population at large, there is a marked inc rease in the risk of developing CHD, i.e. the majority of CHD oc c urs in individuals with c holesterol levels that are distributed near the mean of the population, the CHD risk being graded and c ontinuous without a threshold; only a small frac tion of the disease burden is assoc iated with elevated c holesterol levels that are disc retely separate from the so-c alled 'normal range' of variability. Monogenic traits, suc h as heterozygous familial hyperc holesterolaemia ( FH) , are of Mendelian inheritanc e, but polygenic ally determined c holesterol level is in the offspring approximately halfway between the levels of two parents when the values are measured at about the same age for both generations.
Family studies support genetic testing
Familial aggregation of CHD has long been known and the data have been reviewed. Studies in the 1 9 6 0 s already showed that the first-degree relatives of affec ted patients have approximately 2 -6 -fold higher risk of the disease than those of matc hed c ontrols. The familial aggregation inc reases with dec reasing age of affec ted patients. While women have a lower frequenc y of CHD than men, the firstdegree relatives of index women run a higher risk than those of affec ted index males.
Investigations on premature CHD ( defined as CHD oc c urring before the age of 5 6 years) in Finland showed a 2 .5 -fold higher risk ( relative to general population) for brothers of male CHD c ases and a two-fold higher risk for their sisters. The risk for probands' brothers inc reased with dec reasing age of onset among index c ases. Familial aggregation of CHD was also observed in studies in whic h the index c ases had CHD proved by angiography. The various prospec tive and retrospec tive studies reviewed by Freidlander c learly show familial aggregation of CHD and support an overall signific ant independent assoc iation of family history of CHD, mainly developed at an early stage of life, with the risk for CHD.
Environmental risk fac tors c an have an exaggerated adverse effec t in patients with genetic susc eptibility: c igarette smoking, exc ess body weight, diet, vitamin defic ienc y, and hypertension. There is mutual overlapping influenc e of all those and a genetic trait.
Gene polymorphism and cardiovascular risk
The potentially most important genes for c ardiovasc ular atherosc lerosis risk are listed in the above Table. This is not a final list but rather a list of the hitherto most doc umented genetic risk fac tors. The growing numbers of genetic variants have signific ant implic ation on our rec ognition of the c omplexity of the disease. Altogether, today, more than 8 4 0 variants of different genes are tested and fast growing data from literature need to be reevaluated on the basis of EBM princ iples. As CHD c andidate genes are identified, there is inc reasing need for assays c apable of the simultaneous genotyping of multiple loc i. Studies foc used on single markers c an be used to assign relative risk values, but this approac h provides only a limited c ontext for evaluating genetic risk fac tors. So far it is evident that some genes are more important in some, but not in other populations.
There is muc h c ontroversy on results of published epidemiologic al studies until now. The differenc es might be due to methodologic al fac tors or studied risk groups. In c ontrast to single gene analysis, multiple markers provide insight into mec hanisms of disease susc eptibility and identify the key c luster of predic table markers that are c linic ally informative. New tec hnologies inc luding DNA c hip and mic roarray or reverse-line genotyping might be more important in the future for genetic epidemiology of CHD as well as c linic al medic ine. But before a final dec ision is made and genetic markers are used to supplement routine bioc hemic al assays for patient c are, there is a need for c areful analysis of all studies performed to date.
